Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis - Takeaways - MDSpire

Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis

  • By

  • Yicheng Ling

  • Mengyao Wei

  • Jiapeng Luo

  • Tianxiang Gu

  • Xuan Jiang

  • May 28, 2026

  • 0 min

Share

  • 1

    Serum resistin levels progressively increase with the severity of coronary heart disease, indicating its potential as a biological marker.

  • 2

    The network meta-analysis included 26 studies with 9,169 subjects, revealing significant heterogeneity and publication bias.

  • 3

    Standardized mean differences showed resistin levels highest in acute myocardial infarction, followed by acute coronary syndrome and stable CHD.

  • 4

    Despite its association with CHD severity, resistin is not suitable as a standalone diagnostic tool due to significant variability in findings.

  • 5

    The study suggests resistin may serve as an adjunctive marker in multi-biomarker models for risk stratification, pending further validation.

Original Source(s)

Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis

  • by Yicheng Ling, Mengyao Wei, Jiapeng Luo, Tianxiang Gu, Xuan Jiang

  • May 28, 2026

Related Content

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

Pregnancy-Linked SCAD More Severe

Data presented at the American College of Cardiology 75th Annual Scientific Session linked pregnancy-associated SCAD to more severe presentation and higher in-hospital major adverse cardiovascular events.

Erratum: Association of Gensini Score with 30-Day Mortality Rates in Acute Coronary Syndrome Patients in China